Anavex Life Sciences Corp. Q1 FY2026 earnings call

Christopher Missling discussed the progress of the clinical pipeline, focusing on lead candidate oral blarcamesine in early Alzheimer's disease. Anavex is part of the Access AD European initiative for Alzheimer's disease. Feedback from an FDA Type C meeting was shared, and the CHMP's negative opinion on blarcamesine's marketing authorization application was mentioned with the request for reexamination. Presentations at the CTAD conference were noted, along with upcoming scientific findings and publications. Plans to provide updates on blarcamesine in other indications and future clinical trial designs were outlined.

The reexamination of the CHMP opinion on blarcamesine is expected to last the first half of the year. The company plans to advance towards filing a formal NDA submission with the FDA when closer and will continue with data package submission. Anavex 3-71 is set to be advanced towards pivotal clinical studies for schizophrenia-related disorders.

Uncertainty in clinical trial results and regulatory approvals, need for future capital, maintenance of intellectual property rights, and risk that investigational products may not complete clinical development or gain approval.

Q: Regarding who the rapporteur and co-rapporteur are for the reexamination of the CHMP opinion on blarcamesine?

A: The 27 countries of the EU decide on two rapporteurs.

Q: Timeline for reexamination?

A: It's a 60+60 day period where they respond to the reexamination request and then the review by rapporteurs takes another 60 days, so expected to last first half of the year.

Q: Timeline for formal NDA submission to FDA?

A: In process, will advance closer as they continue with data package submission.

Q: Details on resubmission to EMA?

A: Including data from AD-004 study, AB-clear population data, and correlation of efficacy with brain atrophy reduction.

Q: Trials in progress and near-term timelines?

A: Compassionate use programs ongoing, plans for Parkinson's, fragile X, etc.

Q: CHMP rejection clarity on sigma-1 wild type?

A: Interpretation of trial data differs, AB-clear population shows significance across endpoints with large effect sizes.

Q: New statistical methodology and ADCS ADL endpoint?

A: ADCS ADL not sensitive for early Alzheimer's, new methodology considered.

Q: Reexamination timeline, SAG appointment?

A: Will update on process, Scientific Advisory Group involved.

Q: Phase four trial if approved under CMA?

A: Will run confirmatory study as per regulatory guidelines.

Q: Blarcamesine in Access AD program?

A: Part of placebo-controlled trial for early Alzheimer's, considered AD-006.

Q: Atrophy to clinical improvement analysis?

A: Paper submitted soon.